Biotech Co. Beats Investor Suit Over Antifungal Drug Recall
By Sydney Price · July 31, 2025, 8:43 PM EDT
Biotechnology company Scynexis Inc. has won dismissal, for now, of a proposed investor class action alleging that it triggered a 34% share decline by knowingly misleading investors about manufacturing compliance issues...
To view the full article, register now.